Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Folkhälsan Research Center, Helsinki, Finland.
Ann Med. 2024 Dec;56(1):2412283. doi: 10.1080/07853890.2024.2412283. Epub 2024 Oct 21.
This study aimed to assess whether exposure to hyperglycemia influences prescription medicine purchases in the offspring of women with type 1 diabetes (exposed offspring).
PATIENTS/MATERIALS AND METHODS: We identified all singleton exposed offspring born in the hospital district of Helsinki and Uusimaa, Finland, between 1988 and 2011 from the Finnish Medical Birth Register, maintained by the Finnish Institute for Health and Welfare. For each exposed offspring, we obtained five age- and province-matched offspring of women without diabetes (reference offspring), from the Finnish Medical Birth Register. By combining data from three national registers, this longitudinal cohort study assessed prescription medicine purchases in exposed offspring ( = 1,725) and reference offspring ( = 8,755) from seven to thirty years of age. Prescription medicine purchases were grouped according to the Anatomical Therapeutic Chemical (ATC) classification system.
Between 1995 and 2018, a total of 211,490 prescription medicines were purchased. After a median follow-up of 10.9 (interquartile range 4.9,17.6) years, we observed higher incidence risk ratios (IRR) of prescription medicine purchases for several ATC main groups in exposed offspring compared to reference offspring, with the highest IRR of 4.06 (95% CI: 2.78 to 5.94) for medicines affecting metabolism (e.g. diabetes medicines).
Our findings suggest that exposed offspring purchase more reimbursable prescription medicines than reference offspring from age seven to thirty years. More research is needed to examine the effects of intrauterine exposure to hyperglycemia on long-term health in offspring.
本研究旨在评估母体 1 型糖尿病暴露是否会影响子代的处方药购买情况(暴露子代)。
患者/材料和方法:我们从芬兰卫生与福利研究所维护的芬兰医疗出生登记处确定了 1988 年至 2011 年期间在芬兰赫尔辛基和乌西玛地区出生的所有单胎暴露子代,并为每个暴露子代从芬兰医疗出生登记处获得了 5 名年龄和省份匹配的无糖尿病女性的子代(对照子代)。通过结合来自三个国家登记处的数据,这项纵向队列研究评估了暴露子代( = 1725)和对照子代( = 8755)从 7 岁到 30 岁的处方药购买情况。根据解剖治疗化学(ATC)分类系统对处方药购买情况进行了分组。
在 1995 年至 2018 年期间,共购买了 211490 种处方药。在中位数为 10.9 年(四分位间距 4.9,17.6)的随访后,我们观察到暴露子代的几种 ATC 主要药物组的处方药购买发生率风险比(IRR)高于对照子代,其中影响代谢的药物(如糖尿病药物)的 IRR 最高,为 4.06(95%可信区间:2.78 至 5.94)。
我们的研究结果表明,暴露子代从 7 岁到 30 岁购买的可报销处方药多于对照子代。需要进一步研究宫内高血糖暴露对后代长期健康的影响。